Weekly Innovation Highlights in Life Sciences and Healthcare (No.39): Key Approvals, Partnerships, and Clinical Advances from September 30 to October 8, 2024
Akeso
Innovative Antibody Drug Developer
Daiichi - Sankyo
Pharmaceutical Development, Production, Sales, and Consulting Service Provider
AstraZeneca
Pharmaceutical Technology Research and Development Provider
HUTCHMED
Biopharmaceutical Manufacturer
BeOne
Developer of Molecular Targeted and Immune Anti-Tumor Drugs
Sanofi
Pharmaceutical Manufacturer
Elpiscience
Innovative R&D Provider of Tumor Immunotherapy
DP Technology
Simulation R&D Platform Developer
LEPU BIOPHARMA
Innovative Oncology Treatment Product Developer
Weekly Dynamics in Life and Health (No.39)
2024.9.30-10.8
September 30, October 1,AkesoAkeso announced in succession that its self-developed PD-1/CTLA-4 bispecific antibody, Kaitanni® (Cadonilimab Injection), has been approved for a second indication; its self-developed Class 1 new drug, Yixining® (Inucilimab), has been approved for marketing by the NMPA.
October 1,Daiichi - SankyoAndAstraZenecaJointly announced that the supplemental Biologics License Application for Enhertu (trastuzumab deruxtecan) has been accepted by the FDA and granted priority review.
October 3,HUTCHMEDAiYouTe® (Fruquintinib) Included in the Hong Kong Hospital Authority Drug Formulary, Listed under the "Special Use Medication" Category.
October 4,BeOne MedicinesBeOne Medicines announced that its self-developed Tislelizumab (Tevimbra®) has been launched and is now available for sale in the United States.
October 4,SanofiAgreement reached with Recordati to grant global rights of Enjaymo® (sutimlimab), the world's first and currently only approved C1s monoclonal antibody for the treatment of cold agglutinin disease, to Recordati.
October 7,Genor BiopharmaAnnounced the signing of a merger agreement with Yiteng Pharmaceuticals to acquire Yiteng Pharmaceuticals through a merger.
October 7,AstraZenecaAnnounced an exclusive licensing agreement with CSPC Group to advance the development of a preclinical innovative small molecule lipoprotein(a) inhibitor.
October 8,Insilico MedicineAnnounced a strategic partnership with Heze Saituo Biological Technology Co., Ltd. to jointly advance research in synthetic biology and the development of innovative drugs.
October 8,National Children's Medical Center, Zhangjiang Campus of Shanghai Children's Medical CenterThe first outpatient day has arrived.
Recently,Silicon羿 Technology"Green Manufacturing of RNA Biopesticides" Project Wins the Top Award - Excellence Award at the 2024 China Disruptive Technology Innovation Competition Awards Ceremony.
Recently,MicroPort® RobotThe Honghong® Orthopedic Surgical Robot (Overseas Product Name: SkyWalker™, Abbreviated as “Honghong® Robot”) has been approved for marketing by Japan's Ministry of Health, Labour and Welfare.
Recently,Shanghai University of Traditional Chinese MedicineProfessor Xu Hongxi's Team Reveals the Role of Glutathione Peroxidase 3 in Adipose Tissue Remodeling, Research Published inRedox Biology。
Recently,Shanghai Institute of Materia MedicaResearch Group of Tan Minjia Collaborates to Reveal Metabolic Intervention Mechanism and Diagnostic Markers in High-Risk Prostate Cancer, Study Published inNature Cancer; The team led by Huaqiang Xu summarized the application of diffusion models in AI-assisted antibody design, and the review was published inActa Pharmacologica Sinica。
Recently,ElpiscienceThe latest research findings on ES004-B5, a self-developed SIRPα blocking antibody, were published inAntibody Therapeutics。
Recently,DP TechnologyLEPU BIOPHARMA Announces Key Collaboration on ADC Drugs.
Recently,KoZhikangSigned a strategic cooperation framework agreement with Covar to jointly promote the development of CMC research and regulatory registration services in the Chinese, U.S., Canadian, and European markets.
Recently,BenYao TechnologyOfficially Sign Strategic Cooperation Agreement with Metware, Jointly Build Next-Generation Ultra-High-Throughput Proteomics Automation Workstation.
Recently,Hengrui MedicineHR19042 Capsule, a Class 2.2 Modified New Drug, is Proposed by CDE to be Included in the Breakthrough Therapy Designation for the Treatment of Active Autoimmune Hepatitis.
Recently,Dizhe PharmaceuticalsDZD9008 Tablets (Sunvozertinib) Proposed by CDE for Inclusion in Breakthrough Therapy Designation for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Who Have Not Received Systemic Therapy.
Recently,NuoSheng MedicalComposite Steep Pulse Treatment Device Receives FDA Breakthrough Device Designation and Priority Review Status.
Recently,Hengrui MedicineAndCStone PharmaceuticalsThe CS1002/SHR-8068 (anti-CTLA-4 monoclonal antibody), which has reached a strategic cooperation agreement, has initiated a Phase III clinical trial for first-line treatment of advanced hepatocellular carcinoma in combination with adebrelimab and bevacizumab.
Recently,HenliusHold AI Project Kick-off Meeting with Mingdu Zhiyun to Maximize Digital Value through AI Collaboration.
Recently,Xintong MedicalVitaFlow Liberty® Transcatheter Aortic Valve and Retrievable Delivery System Successfully Conducts First Commercial Clinical Applications in Europe Post-Market Launch in Italy and Spain.
Recently,InnoventGLP Laboratory Receives GLP Certificate Issued by the National Public Health and Medicines Center of Hungary.
(Edited by the Pharm Valley team)
